Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Topix

01:14 EST 24th February 2018 | BioPortfolio

Here are the most relevant search results for "Topix" found in our extensive news archives from over 250 global news sources.

More Information about Topix on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Topix for you to read. Along with our medical data and news we also list Topix Clinical Trials, which are updated daily. BioPortfolio also has a large database of Topix Companies for you to search.

Showing News Articles 1–25 of 3,000+ from Topix

Friday 23rd February 2018

Barclays Cuts United Therapeutics (UTHR) Price Target to $105.00

The brokerage currently has an "underweight" rating on the biotechnology company's stock. Barclays' price target would suggest a potential downside of 14.05% from the stock's previous close.

Cetera Advisor Networks LLC Invests $227,000 in Mylan (MYL) Stock

Cetera Advisor Networks LLC purchased a new position in shares of Mylan in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 5,463 shares of the company's stock, valued at approximately $227,000.

Why small biotech stocks are the best choice for big returns

Each week, a professional investor tells us where he'd put his money. This week: Carl Harald Janson of the International Biotechnology Trust selects three potential acquisition targets in the biotechnology sector.

Weekly Analysts' Ratings Updates for Bristol-Myers Squibb

Several brokerages have updated their recommendations and price targets on shares of Bristol-Myers Squibb in the last few weeks: 2/16/2018 - Bristol-Myers Squibb was given a new $78.00 price target on by analysts at Citigroup Inc. They now have a "buy" rating on the stock. 2/15/2018 - Bristol-Myers Squibb was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" r...

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday. The deal is the latest by a major drugmaker looking to develop lucrative gene therapies that have the potential to treat ailments by directly targeting disease-causing genes.

Thursday 22nd February 2018

Achillion Pharmaceuticals (ACHN) Posts Earnings Results, Misses Estimates By $0.01 EPS

Achillion Pharmaceuticals released its quarterly earnings results on Thursday. The biopharmaceutical company reported earnings per share for the quarter, missing analysts' consensus estimates of by , Bloomberg Earnings reports.

Missing CDC employee left work sick 10 days ago, hasna t been seen since, police say

Police are asking the public for help finding a missing Centers for Disease Control and Prevention employee who went home sick 10 days ago and hasn't been seen or heard from since. Timothy Cunningham, 35, went to work on Feb. 12 and left sick, the Atlanta Police Department said.

Missing CDC employee left work sick 10 days ago, hasn't been seen since, police say

Police are asking the public for help finding a missing Centers for Disease Control and Prevention employee who went home sick 10 days ago and hasn't been seen or heard from since. Timothy Cunningham, 35, went to work on Feb. 12 and left sick, the Atlanta Police Department said.

Anika Therapeutics (ANIK) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Anika Therapeutics issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.41 by , Zacks reports.

Weekly Research Analysts' Ratings Changes for Catalent

According to Zacks, "Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services.

Treatment Debates Won't Slow Down Biotechs

A number of biotech companies, including Gilead Sciences , have staked a lot on CAR-T therapies for cancer patients. Today, Guggenheim's Tony Butler and his team take a look at the debate about one set of side effects for these treatments, but ultimately they don't think they'll slow the adoption of these options.

RPT-INSIGHT-Seed firms scramble to stop a 'cancer' in Canada's cash crop

Inside a laboratory in Winnipeg, Manitoba, a Monsanto Co research technician uses tweezers to transfer pollen from one canola plant to another, a small step toward creating a new breed of the vegetable oil-producing crop. It's an early stage of a high-stakes effort to control the biggest threat to Canada's C$27-billion canola industry - a crop disease called clubroot that presents unique c...

Achillion Announces Restructuring to Advance Corporate Strategy;...

Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet NEW HAVEN, Conn., Feb. 22, 2018 -- Achillion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on developing inhibitors of the complement alternative pathway, today announced an operational restructuri...

RTI Surgical (RTIX) Set to Announce Earnings on Thursday

RTI Surgical is scheduled to be posting its quarterly earnings results before the market opens on Thursday, March 1st. Analysts expect RTI Surgical to post earnings of $0.03 per share for the quarter.

Health care risks being forgotten in Brexit talks, industry warns

The UK pharmaceutical industry has warned that it faces multi-million euro contingency costs to prepare for Brexit. [ Kris A/Flickr ] Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.

Wednesday 21st February 2018

McKesson Co. (MCK) Expected to Announce Quarterly Sales of $51.56 Billion

Wall Street brokerages expect that McKesson Co. will post sales of $51.56 billion for the current fiscal quarter, according to Zacks .

Here's Our New Best Stocks to Buy List

Our latest list of best stocks to buy now gives you five companies with rock-solid balance sheets and that are riding strong trends that can't be disrupted by Wall Street jitters. We love these stocks, because any market downturn - like the 10% drop we just saw - will be just a small blip in these stocks' overall performance.

Alpha 1 Antitrypsin Deficiency Treatment Market: High Unmet Demand in ...

A recent intelligence study by Transparency Market Research has detected that the global alpha-1 antitrypsin deficiency treatment market is divided among a vast number of global and regional players. The report anticipates that this fragmented scenario of the market for alpha-1 antitrypsin will prompt an increase in the number of mergers and acquisitions that can benefit both parties.

Ligand reports 4Q loss

The San Diego-based company said it had a loss of 33 cents per share. Earnings, adjusted for one-time gains and costs, were $1.31 per share.

Mylan (MYL) is Pzena Investment Management LLC's Largest Position

Pzena Investment Management LLC lessened its stake in Mylan by 3.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 21,978,042 shares of the company's stock after selling 743,342 shares during the period.

Amarin (AMRN) Scheduled to Post Quarterly Earnings on Tuesday

Amarin will be issuing its quarterly earnings data before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of per share for the quarter.

Bristol-Myers Squibb Co (BMY) Holdings Trimmed by Strs Ohio

Strs Ohio cut its stake in shares of Bristol-Myers Squibb Co by 6.4% during the 4th quarter, HoldingsChannel reports. The fund owned 1,431,520 shares of the biopharmaceutical company's stock after selling 98,504 shares during the period.

UPDATE 2-Merck to buy virus-based cancer drug firm Viralytics for $394 mln

The idea is to cause cancer cells to rupture and die, while also stimulating a wider immune system response in the body. The deal, which is conditional on no better offer emerging from a counter-bidder, represents a premium of 160 percent to the average stock price over the past month - another example of the outsized offers often needed to clinch biotech takeovers.

Basilea's CEO Ronald Scott will retire. Chief Commercial Officer...

Basilea Pharmaceutica Ltd. reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the company. Basilea's Board of Directors has appointed David Veitch, currently Basilea's Chief Commercial Officer and member of the Management Committee, to succeed Mr. Scott in the role of Chief Executive Officer effective April 19, 2018.

Doctors get rich from controversial drug maker as patients become addicts

Tamisan Witherspoon lost her marriage, her home and her health while two Alabama pain doctors amassed a fortune at her expense. The suburban soccer mom turned couch-potato addict - who overdosed weekly from opioids - blames Drs.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks